Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers found that the cancer drug zavondemstat and a closely related compound QC6352 do not primarily target KDM4, but instead work by blocking DHODH, an enzyme cancer cells rely on to produce molecules needed for rapid growth. This discovery highlights a broader challenge in cancer drug development, emphasizing the need for great...
Researchers at the University of São Paulo found that anti-cancer molecules effective against malaria parasites, eliminating them at both the asexual and gametocyte stages of development. This discovery paves the way for the development of new effective drugs.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A large U.S. insurance claims analysis found that fewer than 30% of patients with hormone receptor-positive early-stage breast cancer remained adherent to endocrine therapy for five years after lumpectomy. Younger age and radiation therapy omission were associated with lower adherence rates.
Studies on hypofractionated postmastectomy radiotherapy, proton therapy for hepatocellular carcinoma, and stereotactic body radiation therapy for Ewing sarcoma showcase improved patient outcomes. The findings also suggest potential benefits for short-course radiation therapy access and patient navigation in cancer centers.
For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a curative treatment option, and trimodal therapy is recommended as an alternative to radical cystectomy. The guideline also provides guidance on radiation therapy after surgery and for patients with metastatic or symptomatic disease.
A new survey by the National Comprehensive Cancer Network (NCCN) reveals that 100% of cancer centers in the US are experiencing a shortage for at least one anti-cancer agent, with 94% noting a shortage of ifosfamide. The survey also found that 71% of centers are experiencing a shortage of carboplatin, a key chemotherapy used to treat v...
A real-world observational study found no significant survival benefit from post-surgery immunotherapy in NSCLC patients with pathological complete response after neoadjuvant chemoimmunotherapy. The study suggests that these patients may already derive the maximum benefit from neoadjuvant therapy alone.
A University of Helsinki research group has discovered a weakness in aggressive breast cancer cells that can be exploited, targeting the MYC protein's metabolic grip. By inhibiting energy production and glutamine uptake, researchers were able to slow breast cancer growth in mice, paving the way for new and personalised treatments.
A UCLA study found that patients with cancer who used biosimilars had lower average monthly costs for insurers and patients, with savings of $3,820 for insurers and $39.50 for patients. The study also found that biosimilar entry led to lower prices and declining market share for the original branded biologic drugs.
A chemotherapy-free combination of targeted therapies showed encouraging results in patients with HR-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option. The regimen produced durable responses while maintaining a manageable safety profile for many patients.
A study published in JAMA Otolaryngology–Head & Neck Surgery found that preoperative chemo-immunotherapy was more effective than immunotherapy alone in reducing tumor size in patients with head and neck cancer. The study analyzed data from 86 adults with head and neck cancer treated between July 2024 and March 2026, and showed that pat...
Recent research explores the use of nanomaterial-based drug delivery to increase treatment efficacy for glioblastoma, a type of brain tumor with poor prognosis. Stimuli-responsive and biomimetic nanomedicines are designed to overcome the blood–brain barrier and deliver drugs selectively within tumors.
Dr. Amoako's evidence-driven services improve early diagnosis, expand access to treatment, and advance locally led research in Ghana. Her work aims to strengthen childhood cancer care across the country.
Researchers have developed an experimental drug that tricks cancer cells into consuming more sugar than usual, then blocks their backup fuel source – fat. This approach puts cancer cells under so much stress that many die, demonstrating effectiveness in treating aggressive melanoma in mice.
A cross-sectional study examines trends in US FDA-approved cancer medicines for adult solid tumors between 2006 and 2025. The analysis reveals significant increases in approvals, particularly for original indication approvals.
Circulating circRNAs show high cell-type and tissue specificity, making them ideal for non-invasive cancer management. They can be detected in multiple body fluids and reflect treatment response, positioning them as functional drivers of therapy resistance.
Dr. Yi Li receives CPRIT funding to develop treatments for solitary fibrous tumor, a rare cancer driven by gene fusions. Researchers are working on novel therapies, including immunotherapy and antisense oligonucleotides, to reduce cancer-causing signal activity.
Researchers have developed a new approach to designing drugs that can target multiple types of cancer cells, significantly improving treatment outcomes in mice. By self-assembling into two antibodies that bind together and attack multiple receptors, the modified antibody-drug conjugates outperformed standard treatments.
Researchers identified why some patients with rare blastic plasmacytoid dendritic cell neoplasm (BPDCN) leukemia don't respond to tagraxofusp. Severe TET2 gene mutations and low TXNRD1 enzyme levels contribute to resistance, suggesting these biomarkers could predict treatment outcomes.
A new prodrug and localized drug delivery platform have been developed by researchers to selectively target cancer cells. The platform uses carbamate masking of the 4-anilinoquinazoline hinge nitrogen to modulate exposure and enable controlled activation of EGFR-TKIs in tumour microenvironments.
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
A new study shows that targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype. After two years, 92% of patients remained cancer-free, compared to 61% who received a placebo.
Researchers at MUSC Hollings Cancer Center have identified a potential way to reduce relapse in medulloblastoma by targeting tumor cells most likely to survive treatment and drive regrowth. The dual-pathway approach, focusing on CK1α, shows promise in preclinical models.
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
Researchers from UH, Baylor College of Medicine and MD Anderson Cancer Center propose a new treatment approach for Crohn's disease by targeting the stress signal that fuels inflammation. They found that repurposing two existing cancer medications can promote natural repair and regeneration of the intestinal lining.
A new treatment using low-dose nivolumab injections into precancerous oral lesions significantly reduced lesion size and risk of cancer progression. The study showed a 60% average reduction in lesion size and complete pathologic response in six patients, with no dose-limiting side effects.
The hospital is conducting a phase 2 clinical trial evaluating STAR0602, which activates the immune system to stop tumor growth across various cancers. The goal of this study is to identify safer and more effective treatments for people with advanced cancers.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
A study found that tumor DNA in patients' blood can predict whether breast cancer will return, especially after neoadjuvant treatment. Patients with detectable DNA at the end of treatment were 3.5 times more likely to relapse during follow-up.
A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.
A new analysis shows elinzanetant effectively relieves moderate-to-severe vasomotor symptoms (VMS) associated with endocrine therapy, regardless of the type of hormone treatment. The drug reduces VMS frequency and severity by blocking a protein that triggers these symptoms.
Researchers successfully treated drug-resistant strains of herpes using doxorubicin, a known anticancer drug. The treatment works by targeting a pathway used by the virus, preventing infection and potentially saving lives for vulnerable patients.
A novel drug delivery system developed by Osaka Metropolitan University improves Paclitaxel absorption by binding to the lipocalin-type prostaglandin D synthase enzyme, enabling selective delivery to cancer tissues. The system demonstrates significant tumor suppression effects even after administration cessation.
Researchers have identified and resolved molecular bottlenecks to produce doxorubicin, a vital chemotherapy agent, resulting in a 180% increase in production. This breakthrough enables cost-effective manufacturing of essential antibiotics and anti-cancer agents, promising a cleaner and more reliable supply of life-saving medicines.
Researchers at Duke University have developed a technique using microbubbles and ultrasound to deliver large cancer drugs into cells, causing them to self-destruct. The technology, called SonoPIN, shows promise in precisely delivering therapeutics to cancer cells with minimal off-target effects.
Researchers discovered yaku'amide B induces CD9 degradation, a cancer stem cell-related protein, in addition to inhibiting ATP synthase, leading to cellular energy depletion and cancer cell suppression. This natural compound has potential as a new therapeutic approach for cancer treatment.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Researchers discover a potential chemotherapy agent that causes cancer cells to release signals similar to those released by infected cells, triggering an immune response. This finding could lead to a new approach in cancer treatment, using lower doses of chemotherapy drugs to recruit the immune system as an ally.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Approximately 40 cancer patients will receive LMP744 for five consecutive days, with biological analyses conducted on brain tissues before and after treatment. If results are favorable, treatment will continue for 12 cycles to evaluate parameters such as progression-free survival and overall survival.
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
The conference aims to improve genetic studies, clinical best practices and community interventions to combat the increasing cancer incidence rates. It will bring together top cancer-focused minds to promote precision medicine and stimulate multidisciplinary collaborations for cancer solutions.
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
The PATINA trial demonstrates a significant progression-free survival benefit with palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The study showed a median progression-free survival of 44.3 months, compared to 29.1 months in the control arm.
Scientists at Northwestern University have determined the three-dimensional structures of rye pollen's cancer-fighting molecules, secalosides A and B. This breakthrough opens the door to exploring how these molecules interact with the immune system and could inspire new approaches to cancer therapy.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
A Mass General Brigham study identifies new mutations that emerge in tumor cells following treatment, driving resistance in patients with different types of cancer. The researchers found two main categories of mutations: those impairing p53 function and others disrupting drug binding, highlighting a path forward for overcoming resistance.
Researchers create a novel mathematical framework to control biological noise, enabling precise single-cell control. The 'Noise Robust Perfect Adaptation' technology suppresses stochastic fluctuations while maintaining stable average behavior, with promising applications in cancer therapy and synthetic biology.
A study published in EMBO Molecular Medicine has identified a combination of statins and phenothiazines that shows promise in treating aggressive neuroblastoma. The drug combination was found to impede tumour growth and improve survival rates in laboratory trials with mice.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
A new oral endocrine therapy, giredestrant, has been shown to significantly lower the risk of breast cancer recurrence in early-stage HR-positive/HER2-negative patients. In a large clinical trial, patients treated with giredestrant were 30% less likely to have invasive disease recur or progress.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
Researchers at Insilico Medicine developed an AI-empowered dual-action PROTAC targeting PKMYT1, which induces degradation and inhibits kinase activity. The lead compound, D16-M1P2, exhibits high selectivity, potent anti-tumor activity, and favorable oral bioavailability.
Australian researchers have discovered a drug combination that can bypass the cellular defenses developed by neuroblastoma tumors, making it more effective against relapsed cases. The combination reduces tumor growth and extends survival time compared to standard treatment alone.
A new study reveals that kinase inhibitors can accelerate the degradation of targeted proteins, which is not a rare quirk but a common mechanism. This discovery could help design better drugs that remove kinases altogether or explain unexpected effects of existing therapies.
A new study has developed a calcium-activated delivery system that enables more precise cancer treatment, reducing side effects and improving outcomes. The system uses a 'calcium switch' to target tumor cells, releasing a lethal payload deep within, while sparing healthy tissue.